Alembic Pharmaceuticals Intrinsic Value
APLLTD Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹827.20 | ₹661.76 - ₹992.64 | +1.5% | EPS: ₹37.60, Sector P/E: 22x |
| Book Value Method | asset | ₹2036.88 | ₹1833.19 - ₹2240.57 | +150.0% | Book Value/Share: ₹1330.77, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1629.50 | ₹1466.55 - ₹1792.45 | +100.0% | Revenue/Share: ₹1968.21, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1629.50 | ₹1466.55 - ₹1792.45 | +100.0% | EBITDA: ₹1296.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹325.90 | ₹260.72 - ₹391.08 | -60.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹244.42 | ₹219.98 - ₹268.86 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹580.92 | ₹522.83 - ₹639.01 | -28.7% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹1629.50 | ₹1466.55 - ₹1792.45 | +100.0% | ROE: 14.2%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹1061.05 | ₹954.94 - ₹1167.15 | +30.2% | EPS: ₹37.60, BVPS: ₹1330.77 |
Want to compare with current market value? Check APLLTD share price latest .
Valuation Comparison Chart
APLLTD Intrinsic Value Analysis
What is the intrinsic value of APLLTD?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Alembic Pharmaceuticals (APLLTD) is ₹1061.05 (median value). With the current market price of ₹814.75, this represents a +30.2% variance from our estimated fair value.
The valuation range spans from ₹244.42 to ₹2036.88, indicating ₹244.42 - ₹2036.88.
Is APLLTD undervalued or overvalued?
Based on our multi-method analysis, Alembic Pharmaceuticals (APLLTD) appears to be trading below calculated value by approximately 30.2%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 23.91 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.50 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 14.2% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 17.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.99x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Alembic Pharmaceuticals
Additional stock information and data for APLLTD
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹88 Cr | ₹-196 Cr | Positive Operating Cash Flow | 6/10 |
| March 2024 | ₹803 Cr | ₹643 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹724 Cr | ₹500 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹552 Cr | ₹366 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹1,463 Cr | ₹1,043 Cr | Positive Free Cash Flow | 8/10 |